Treatment agents and methods for treating type II diabetes and s

Details Treatment agents and methods for treating type II diabetes and s Treatment agents and methods for treating type II diabetes and s

1997-12-19

1999-07-27

MacMillan, Keith D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514171, A61K 3158, A61K 3156, A61K 3100

Patent

active

059290587

ABSTRACT:
Methods for treating non-insulin dependent Diabetes Mellitus (NIDDM), or Type II Diabetes, by administering a combination of treatment agents exhibiting glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are disclosed. Treatment agents having both glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are also disclosed. Screening methods for identifying compounds having both glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are disclosed.

REFERENCES:
patent: 4981784 (1991-01-01), Evans et al.
patent: 5217867 (1993-06-01), Evans et al.
patent: 5232917 (1993-08-01), Bolger et al.
patent: 5262300 (1993-11-01), Evans et al.
patent: 5310662 (1994-05-01), Evans et al.
Database Chemical Abstracts on STN, AN 1995:396499, Kornel et al, "Aldosterone increases transmembrane influx of Na+ in vascular smooth muscle cells through increased synthesis of Na Channels", Steroids, (1995), 60(1), 114-19, Jan. 1995.
Santiago M. Valle, et al., Further Studies in Deoxycorticosterone Acetate Treated Rats: Brain Content of Mineralocorticoid and Glucocorticoid Receptors and Effect of Steroid Antagonists on Salt Intake, Neuroendocrinology, 61: 117-124, 1995.
Atsuhisa Sata et al., High Glucose Stimulates Aldosterone-Induced Hyertrophy via Type I Mineralocortoid Receptors in Neonatal Rat Cardiomyocytes, Endocrinology 137(10): 4145-4153, 1996.
Mary F. Dallman et al., Feast and Famine: Critical Role of Glucocorticoids with Insulin in Daily Energy Flow, Frontiers in Neuroendocrinology, 14(4): 303-347, 1993.
DN Brindley, Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome, International Journal of Obesity 19(1), S69-S75, 1995.
Stuart Chalew et al., The Hypothalamic-Pituitary-Adrenal Axis in Obesity, Obesity Research 3(4), 371-382, 1995.
Chen et al., Type II glucocorticoid receptors in the CNS regulate metabolism in ob/ob mice independent of protein synthesis, Dept.of Food Science & Human Nutrition, Michigan State Univ., E427-432, 1994.
A. F. Debons et al., Gold Thiglucose-Induced Hypothalamic Damage, Hyperphagia, and Obesity: Dependence on the Adrenal Gland, Endocrinology 110(6): 2024-2029.
Craig C. Smith, Differential Mineralocorticoid (Type 1) and Glucocorticoid (Type 2) Receptor Expression in Lewis and Fischer Rats, Neuroimmunomodulation I: 66-73, 1994.
Chen et al., A Single Intracerebroventricular Injection of Dexamethasone Elevates Food Intake and Plasma Insulin and Depresses Metabolic Rates in Adrenalectomized Obese (ob/ob) Mice .sup.1,2, Dept. of Food Science and Human Nutrition, Michigan State University, 540-545, 1994.
Saito et al., Adrenalectomy and food restriction in the genetically obese (ob/ob) mouse. Am. J. Physiol. 246: R-20-R25, 1984.
George A. Bray, Food Intake, Sympathetic Activity, and Adrenal Steroids, Brain Research Bulletin 32, pp. 537-541, 1993.

Affiliated with

Also associated with

Rating

Treatment agents and methods for treating type II diabetes and s does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment agents and methods for treating type II diabetes and s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment agents and methods for treating type II diabetes and s will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-878893